BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    BARD® BRACHYSOURCE® I-125 IMPLANT SEED

    MDR report key: 7488238 · Received May 4, 2018

    Report

    Report Number
    1018233-2018-01525
    Event Type
    Malfunction
    Date Received
    May 4, 2018
    Date of Event
    April 9, 2018
    Report Date
    July 13, 2018
    Manufacturer
    BARD BRACHYTHERAPY, INC. -1424526
    Product Code
    KXK
    UDI-DI
    00801741078200
    PMA / PMN Number
    K093663
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    CA, US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL

    Narratives

    Additional Manufacturer Narrative · 0

    THE REPORTED ISSUE WAS CONFIRMED, AS MANUFACTURING-RELATED. BASED ON THE PRODUCT RETURNED FROM SUTTER HEALTH. THE ROOT CAUSE OF THIS COMPLAINT WAS A RESULT OF SWITCHED SHIPPING DOCUMENTATION AT BBI WHEN THE AFFECTED ORDERS WERE BEING PACKAGED AND SHIPPED. THE DEVICE HISTORY RECORD WAS REVIEWED AND FOUND NOTHING THAT COULD HAVE CAUSED OR CONTRIBUTED TO THE REPORTED EVENT. THE INSTRUCTIONS FOR USE STATES THE FOLLOWING: ¿BRACHYSOURCE® SEED IMPLANTS IN MICK® CARTRIDGES ARE BRACHYSOURCE® SEED IMPLANTS LOADED INTO MICK® CARTRIDGES (1-20 BRACHYSOURCE® SEED IMPLANTS PER CARTRIDGE) AND ARE DESIGNED FOR USE WITH THE MICK® 200-TPV APPLICATOR AND WITH APPLICATOR IMPLANT NEEDLES SUPPLIED FOR USE BY BARD. PER THE CUSTOMER¿S REQUEST, THE ORDER MAY ALSO CONTAIN CALIBRATED OR LOOSE BRACHYSOURCE® SEED IMPLANTS IN A SEPARATE SCREW-CAP VIAL, AND INDIVIDUAL PACKETS OF SOURCELINK® CONNECTORS (SEE THE SOURCELINK® CONNECTOR INFORMATION FOR USE FOR FURTHER INFORMATION REGARDING SOURCELINK® CONNECTORS). ALL COMPONENTS ARE PROVIDED STERILE. PHYSICAL CHARACTERISTICS BRACHYSOURCE® SEED IMPLANTS CONSIST OF A WELDED TITANIUM CAPSULE CONTAINING IODINE-125 ADSORBED ONTO A NICKEL/COPPER COATED, GOLD CORED ALUMINUM WIRE. IODINE-125 HAS A HALF-LIFE OF 59.6 DAYS1 AND DECAYS BY ELECTRON CAPTURE WITH THE EMISSION OF CHARACTERISTIC PHOTONS AND AUGER ELECTRONS. THE PRINCIPAL PHOTON EMISSIONS ARE 27.4 AND 31 KEV X-RAYS AND A 35.5 KEV GAMMA. THE TITANIUM WALL OF THE BRACHYSOURCE® SEED IMPLANTS ABSORBS THE ELECTRONS. IN-VIVO CHARACTERISTICS CLINICAL EFFICACY DERIVES SOLELY FROM THE INTERACTION OF THE EMITTED IONIZING RADIATION FROM THE BRACHYSOURCE® SEED IMPLANTS WITH THE TISSUE BEING TREATED. TITANIUM ENCAPSULATION PROVIDES GOOD BIOCOMPATIBILITY. TOTAL PHOTON TRANSMISSION IS APPROXIMATELY 59%2 AFTER ACCOUNTING FOR ATTENUATION BY THE TITANIUM CAPSULE AND THE RADIO-OPAQUE SOLID SUBSTRATE. DOSE DISTRIBUTION AROUND BRACHYSOURCE® SEED IMPLANTS IS MODERATELY ANISOTROPIC, AS IS COMMON WITH OTHER BRACHYTHERAPY SOURCES,3,4,5 AND SHOULD BE ACCOUNTED FOR IN DOSE CALCULATIONS. INDICATIONS BRACHYSOURCE® SEED IMPLANTS ARE INDICATED FOR PERMANENT INTERSTITIAL TREATMENT OF SELECTED LOCALIZED TUMORS SUCH AS: HEAD AND NECK, LUNG, PANCREAS, AND EARLY STAGE PROSTATE. BRACHYSOURCE® SEED IMPLANTS MAY BE USED IN SUPERFICIAL, INTRA-ABDOMINAL AND INTRA-THORACIC LOCATIONS. BRACHYSOURCE® SEED IMPLANTS ARE INDICATED TO TREAT RESIDUAL TUMORS FOLLOWING COMPLETION OF A COURSE OF EXTERNAL RADIATION THERAPY AND FOR RECURRENT TUMORS. CONTRAINDICATIONS AS WITH OTHER BRACHYTHERAPY SOURCES, TREATMENT OF TUMORS IN GENERALLY POOR CONDITION [E.G. ULCERATED] IS NOT RECOMMENDED WITH BRACHYSOURCE® SEED IMPLANTS DUE TO THE POTENTIAL OF BRACHYTHERAPY SOURCE MIGRATION." BM-RAP-18-04-004 IS ASSOCIATED WITH THIS EVENT. CORRECTION: CONCOMITANT MEDICAL PRODUCTS AND DEVICE EVALUATED BY MFR.

    Description of Event or Problem · 0

    IT WAS REPORTED THAT THE FACILITY RECEIVED SEEDS WITH PRODUCT CODES 1251CSR AND 1251CSRA (SALES ORDER #6971841) THAT WERE INTENDED FOR A DIFFERENT FACILITY INSTEAD OF THE SEEDS THAT WERE ORDERED (PS1251LS - SALES ORDER #6971941). THE INITIAL INVESTIGATION INTO THE ISSUE INDICATES THAT THE FEDEX LABELS ON THE OUTER SHIPPING BOXES WERE SWITCHED. THE PATIENT WAS REPORTEDLY UNABLE TO UNDERGO THE SCHEDULED SURGERY AND AN ADDITIONAL SURGERY WAS SCHEDULED FOR A LATER DATE. THIS FACILITY WAS UNABLE TO COMPLETE THE SCHEDULED PROCEDURE FOR THEIR PATIENT; HOWEVER, THE SEEDS ALLEGED AGAINST (PS1251LS) WERE USED ON A PATIENT AT ANOTHER FACILITY (PIEDMONT HENRY HOSPITAL) IT WAS LATER REPORTED, THE PATIENT'S SURGERY WAS RESCHEDULED AND COMPLETED ON 04/18/2018.

    Additional Manufacturer Narrative · 1

    THE INVESTIGATION IS STILL IN PROGRESS. ONCE THE INVESTIGATION IS COMPLETE A SUPPLEMENTAL REPORT WILL BE FILED. (B)(4) IS ASSOCIATED WITH THIS EVENT. THE INFORMATION PROVIDED BY BARD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BARD. THE DEVICE WAS NOT RETURNED.

    Description of Event or Problem · 1

    IT WAS REPORTED THAT THE FACILITY RECEIVED SEEDS WITH PRODUCT CODES 1251CSR AND 1251CSRA (SALES ORDER (B)(4)) THAT WERE INTENDED FOR A DIFFERENT FACILITY INSTEAD OF THE SEEDS THAT WERE ORDERED (PS1251LS - SALES ORDER (B)(4)). THE INITIAL INVESTIGATION INTO THE ISSUE INDICATES THAT THE FEDEX LABELS ON THE OUTER SHIPPING BOXES WERE SWITCHED. THE PATIENT WAS REPORTEDLY UNABLE TO UNDERGO THE SCHEDULED SURGERY AND AN ADDITIONAL SURGERY WAS SCHEDULED FOR A LATER DATE. THIS FACILITY WAS UNABLE TO COMPLETE THE SCHEDULED PROCEDURE FOR THEIR PATIENT; THEREFORE, AN ADDITIONAL SURGERY WAS SCHEDULED. HOWEVER, THE SEEDS ALLEGED AGAINST (PS1251LS) WERE USED ON A PATIENT AT ANOTHER FACILITY ((B)(6) HOSPITAL) PER ADDITIONAL INFORMATION RECEIVED, THE PATIENT'S SURGERY WAS RESCHEDULED AND COMPLETED ON (B)(6) 2018.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    331734 BARD® BRACHYSOURCE® I-125 IMPLANT SEED SEEDS KXK BARD BRACHYTHERAPY, INC. -1424526 PS1251LS BBCQ0050 00801741078200

    Patients

    Seq Age Sex Outcome Treatment
    1